glp-1 inflammation Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1 drugs calm inflammation beyond
Description
In the fourth quarter of 2024, GLP-1 sales accounted for 30% of Himss $481 million in total revenue, and it was estimated that Hims was responsible for 20% of all compounded GLP-1 prescriptions in the US during that period
Nausea, constipation , and fatigue are the most commonly reported issues
It can also be used to prevent surface adsorption of the drug to the container
Phase 3 SYNCHRONIZE trials for obesity are fully enrolled with results expected H1 2026
Contributor Information Ryan J
Gut inflammation is associated with alterations in intestinal motility
